Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma
Ahmad Halwani(University of Utah), Christopher R. Flowers(The University of Texas MD Anderson Cancer Center), Kim Linton(The Christie NHS Foundation Trust), Adam J. Yakovich(Nationwide Children's Hospital), Ian Chau(Royal Marsden NHS Foundation Trust), Hailing Lu(University of Washington), Alex F. Herrera(City of Hope), Roch Houot(Inserm), Frank J. Hsu(Sanofi (France)), Weiyun Z. Ai(City College of San Francisco), Javier Briones(Hospital de Sant Pau), Elizabeth H. Cull(Prisma Health), Iris Isufi(Yale University), Carlos Panizo, Jorge Chaves(Northwest Medical Specialties), Locke J. Bryan(Augusta University Health), Nancy L. Bartlett(Washington University in St. Louis), Sergey Yurasov(Memorial Sloan Kettering Cancer Center), Béla Kis(Moffitt Cancer Center), Craig Okada(Oregon Health & Science University), Michael Chen(University of California, Los Angeles), Gottfried R. von Keudell(Memorial Sloan Kettering Cancer Center), ter Meulen JH, Luis de la Cruz‐Merino
Cited by 20
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k